SEC filing record
Primary Source · SEC.gov

NexPoint Life Sciences II DST

2023 vintageRule 506(c), Section 3(c), 3C.5Filing record

Built from the SEC filing index the day the filing landed. The figures below are the issuer's own from Form D; AltStreet's analysis, sponsor link and data flags follow when the entity is enriched.

Latest signalInvestors increasedForm D/A · 2025-11-2018 events: 9 investors increased, 9 sold increasedLast filing 2025-11-20

Raised

$40M

Investors

112

Min Invest

$100,000

AltStreet Verified Issuer badge

Is this your company or fund? Claim this page free, or verify it and carry the Verified Issuer mark.

What this filing shows

·

Every sentence is a value as filed on SEC Form D

NexPoint Life Sciences II DST is a Delaware entity that first filed a Form D on September 14, 2023 and most recently amended it on November 20, 2025 in the Other Real Estate industry group. The offering claims Rule 506(c), Section 3(c), 3C.5 and covers equity. NexPoint Life Sciences II DST reported $40,489,695 sold from 112 investors of a $40,489,695 total offering as of the Form D filed November 20, 2025. The offering relies on Rule 506(c), so the issuer may advertise it but may sell only to investors it has verified as accredited. The filing reports no non-accredited investors. The minimum investment accepted from an outside investor is $100,000. The Form D names Emerson Equity LLC (CRD 130032), associated with None; Centaurus Financial, Inc. (CRD 30833), associated with None; Arkadios Capital (CRD 282710), associated with None; Coastal Equities, Inc. (CRD 23769), associated with None and 17 others as recipients of sales compensation soliciting in AZ, CA, FL, NY. Sales commissions are reported as $3,542,849 and finders' fees as $0. Form D allows these to be estimates. The issuer's address of record is 300 Crescent Court, Suite 700, Dallas, TX 75201.

EDGAR Filing Data

Form D — Primary Source

View on SEC.gov
CIK Number0001980223
Entity NameNexPoint Life Sciences II DST
ExemptionRule 506(c), Section 3(c), 3C.5
What the exemption meansRule 506(c) of Regulation D: the issuer may advertise the offering publicly, but every purchaser must be a verified accredited investor. Section 3(c) of the Investment Company Act of 1940: the issuer is a pooled investment vehicle relying on an exclusion from registration as an investment company.
Entity TypeOther
Jurisdiction of OrganizationDelaware
Issuer Address300 Crescent Court, Suite 700, Dallas, TX 75201
Phone(833) 697-6246
Industry / Fund TypeOther Real Estate
Investment Company ActExcluded under Section 3(c)
Securities TypeEquity
First Sale DateJune 20, 2023
Filing DateNovember 20, 2025
Accession Number0001980223-25-000005
Total Offering Amount$40,489,695
Total Amount Sold$40,489,695
Amount Remaining$0
Total Investors112
Non-Accredited InvestorsNone
Minimum Investment$100,000
Offering DurationOne year or less
Sales Commissions$3,542,849 (to Emerson Equity LLC and 20 others)
Finders' Fees$0
Revenue RangeDecline to Disclose
State (Issuer Address)TX
Amendment Count19 filings on record

Filings on Record

Every filing AltStreet's ledger holds for this CIK, newest first (15 of 19). Each opens the SEC archive folder.

In the Terminal

Filing events

18

latest Nov 20, 2025

Critical / warning

0 / 0

1 watch · 17 info

Statements extracted

0

none on file

NAV prints

0

none on file

Offering chains

1

closed

Latest event Sold increase · Nov 20, 2025

SEC.gov
Open in the terminal Watch this issuerInvestor $149/mo unlocks the values; Pro $349/mo adds the universe.

Fund family Part of the NexPoint Life Sciences DST family: 3 vehicles across 2 generations · full family and the filing behind each link in the terminal

Investor

  • The full fund family and any related vehicles (parallel, feeder, successor, sibling series) with the filing that shows each link
  • 18 filing events with values and deltas, latest 2025-11-20, and alerts on the next one
  • 1 offering timeline: velocity, share raised, first-sale lag, stalled flags

Pro

  • This issuer against its cohort: rank by velocity and share raised among offerings filed the same quarter
  • The same events, statements and NAV moves across every issuer, screenable, with unlimited watches and CSV

Counts and dates above are the free record. The values, the series and the comparisons are the seat. Loading your view…

Related Persons (Form D)

Executive officers, directors, and promoters listed on the SEC Form D filing. Source: SEC.gov.

NexPoint Real Estate Advisors IV, L.P.

Executive Officer · Dallas, TX

Sponsor of the Issuer

Matthew Goetz

Executive Officer · Dallas, TX

Authorized Signatory of the Issuer

NREA Life Sciences II, LLC

Executive Officer · Dallas, TX

Manager and Signatory Trustee of the Issuer

NREA LS II Investment Co, LLC

Executive Officer · Dallas, TX

Contributor of the Issuer

Matt McGraner

Executive Officer · Dallad, TX

Authorized Signatory of the Issuer

Placement Agents and Sales Compensation (Form D)

Who the issuer reported paying to sell the securities (Form D Item 12), with the FINRA registration number the filer gave. Source: SEC.gov.

Emerson Equity LLCCRD 130032 on BrokerCheck

Associated broker-dealer: None · San Mateo, CA · Soliciting in AZ, CA, FL, NY

Centaurus Financial, Inc.CRD 30833 on BrokerCheck

Associated broker-dealer: None · Anaheim, CA · Soliciting in AZ, CA, CO, HI, MT, PA, UT, WA

Arkadios CapitalCRD 282710 on BrokerCheck

Associated broker-dealer: None · Atlanta, GA · Soliciting in CA, TX

Coastal Equities, Inc.CRD 23769 on BrokerCheck

Associated broker-dealer: None · Wilmington, DE · Soliciting in CA, UT

DMK Advisor Group, Inc.CRD 41067 on BrokerCheck

Associated broker-dealer: None · Lutz, FL · Soliciting in OR

Concorde Investment Services, LLCCRD 151604 on BrokerCheck

Associated broker-dealer: None · Livonia, MI · Soliciting in AZ, CA, FL, KY, MA, PA, UT

Great Point Capital LLCCRD 114203 on BrokerCheck

Associated broker-dealer: None · Chicago, IL · Soliciting in MO

Patrick Capital Markets, LLCCRD 16518 on BrokerCheck

Associated broker-dealer: None · St. Louis, MO · Soliciting in GA, ME

Infinity Financial ServicesCRD 144302 on BrokerCheck

Associated broker-dealer: None · Oakland, CA · Soliciting in TX

Lightpath Capital, Inc.CRD 34617 on BrokerCheck

Associated broker-dealer: None · Southlake, TX · Soliciting in CA, MT

DFPG Investments, LLCCRD 155576 on BrokerCheck

Associated broker-dealer: None · Sandy, UT · Soliciting in CA, MO, OR, TN

Realta Equities, Inc.CRD 23769 on BrokerCheck

Associated broker-dealer: None · Wilmington, DE · Soliciting in CA, CT

Innovation Partners LLCCRD 146344 on BrokerCheck

Associated broker-dealer: None · Charlotte, NC · Soliciting in CA, FL

Moloney Securities Co., Inc.CRD 38535 on BrokerCheck

Associated broker-dealer: None · Manchester, MO · Soliciting in CO

Realized Financial, Inc.CRD 22333 on BrokerCheck

Associated broker-dealer: None · Austin, TX · Soliciting in CA

TCFG Wealth Management, LLCCRD 164153 on BrokerCheck

Associated broker-dealer: None · Laguna Niguel, CA · Soliciting in CA

Westpark Capital, Inc.CRD 39914 on BrokerCheck

Associated broker-dealer: None · Los Angeles, CA · Soliciting in CA, IA

World Equity Group, Inc.CRD 29087 on BrokerCheck

Associated broker-dealer: None · Schaumburg, IL · Soliciting in FL

Aurora SecuritiesCRD 46147 on BrokerCheck

Associated broker-dealer: None · Troy, MI · Soliciting in UT

Saxony Securities, Inc.CRD 115547 on BrokerCheck

Associated broker-dealer: None · St. Louis, MO · Soliciting in CO

Westpark Capital, Inc.CRD 108275 on BrokerCheck

Associated broker-dealer: None · New York, NY · Soliciting in CA

Questions About NexPoint Life Sciences II DST

Each answer is built from the values on the SEC filing and the AltStreet ledger, not from the issuer's marketing.

What is NexPoint Life Sciences II DST?

NexPoint Life Sciences II DST is a Delaware entity that filed a Form D with the SEC on November 20, 2025 in the Other Real Estate industry group. The filing claims Rule 506(c), Section 3(c), 3C.5 for an offering of equity.

Is NexPoint Life Sciences II DST legit?

AltStreet does not rate legitimacy; it reports the public record. NexPoint Life Sciences II DST filed a Form D with the SEC on November 20, 2025 claiming Rule 506(c), Section 3(c), 3C.5. A Form D is a notice of an exempt offering, not a review or approval of it. The newest notice reports $40,489,695 sold to 112 investors. AltStreet's enforcement record (SEC, FINRA and state actions) shows no action naming the issuer as of today. Before investing, confirm the filing on EDGAR, check the seller's registration on FINRA BrokerCheck, and read the offering documents, which a Form D does not include.

Is NexPoint Life Sciences II DST registered with or approved by the SEC?

No. A Form D is a notice that an issuer is selling securities under an exemption from registration, and the SEC does not review, approve, or pass on the merits of the offering. The filing shows that NexPoint Life Sciences II DST claimed Rule 506(c), Section 3(c), 3C.5 and disclosed the items the form requires, such as the amount sold, the minimum investment, related persons, and anyone paid to sell the securities. It does not verify the issuer's claims or its business.

How much has NexPoint Life Sciences II DST raised?

NexPoint Life Sciences II DST reported $40,489,695 sold from 112 investors of a $40,489,695 total offering as of the Form D filed November 20, 2025.

Who can invest in NexPoint Life Sciences II DST?

The offering relies on Rule 506(c), so the issuer may advertise it but may sell only to investors it has verified as accredited. The filing reports no non-accredited investors. The minimum investment accepted from an outside investor is $100,000.

What is the minimum investment in NexPoint Life Sciences II DST?

The Form D lists $100,000 as the minimum investment accepted from any outside investor as of November 20, 2025. Issuers can waive their own minimums, and the figure does not include fees.

Who is selling NexPoint Life Sciences II DST and how are they paid?

The Form D names Emerson Equity LLC (CRD 130032), associated with None; Centaurus Financial, Inc. (CRD 30833), associated with None; Arkadios Capital (CRD 282710), associated with None; Coastal Equities, Inc. (CRD 23769), associated with None and 17 others as recipients of sales compensation soliciting in AZ, CA, FL, NY. Sales commissions are reported as $3,542,849 and finders' fees as $0. Form D allows these to be estimates.

Who is behind NexPoint Life Sciences II DST?

The Form D lists 5 related persons: NexPoint Real Estate Advisors IV, L.P., executive officer (Sponsor of the Issuer); Matthew Goetz, executive officer (Authorized Signatory of the Issuer); NREA Life Sciences II, LLC, executive officer (Manager and Signatory Trustee of the Issuer); NREA LS II Investment Co, LLC, executive officer (Contributor of the Issuer); Matt McGraner, executive officer (Authorized Signatory of the Issuer). Form D Item 3 requires executive officers, directors, and promoters of the issuer to be listed.

Where is NexPoint Life Sciences II DST located?

The issuer's address on its SEC filings is 300 Crescent Court, Suite 700, Dallas, TX 75201. Its phone number of record is 833-697-6246. It is organized under the laws of Delaware.

How long is the NexPoint Life Sciences II DST offering open?

The issuer indicated that the offering is not intended to last more than one year. An issuer must amend its Form D annually while a continuing offering stays open; 15 amendments are on record for this CIK.

What is NexPoint Life Sciences II DST's revenue?

The issuer declined to disclose its revenue range on the Form D, which the form permits.

AltStreet Verified Issuer badge

Is this your company or fund?

Free claim: add your contact details, website, team and a description to this page. The filed facts stay as filed.

Verified Issuer, $480 a year: AltStreet checks the identity of your company and the authority of the person claiming it against your filings, confirms your contact details on a stated date and again at each renewal, and marks the page so people researching you find a current, attributed profile beside the public filing record. It is not a review of any offering.

Data Methodology

Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. EDGAR entity profiles and deal-level data are reviewed by AltStreet analysts with backgrounds in corporate finance and securities law — cross-referenced against offering circulars, audited financial statements, and primary regulatory filings before publication. Platform-provided information, where present, is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. Platforms may request factual corrections for demonstrable inaccuracies by contacting [email protected]. This page does not constitute investment advice.